Boldanic LLC – Trademark Portfolio

Entity Type: 16

Boldanic LLC holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EQUIUM. The owner is based in Brooklyn, NY.

1725 Emmons avenue

C11

Brooklyn, NY 11235

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EQUIUM
EQUIUM
Registered 2019
ALTAJIT
ALTAJIT
Cancelled 2018
BOLDANIC
BOLDANIC
Abandoned 2016
ECDYNIZE
ECDYNIZE
Cancelled 2016
EXUBOL
EXUBOL
Cancelled 2016

Trademark Classifications

Boldanic LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

40
Treatment & Processing (1 filing)

Treatment of materials

Frequently Asked Questions

How many trademarks does Boldanic LLC have?

Boldanic LLC has 6 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 4 cancelled.

What trademark classes does Boldanic LLC file in?

Boldanic LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Boldanic LLC's most well-known trademarks?

Boldanic LLC's registered trademark portfolio includes well-known marks such as EQUIUM. These are among 1 currently registered trademark in the portfolio.

What is Boldanic LLC's trademark registration success rate?

Boldanic LLC has a 17% trademark registration rate, with 1 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.